A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.

Trial Details

NCT ID

NCT07284849

Phase

PHASE3

Sponsor

Incyte Corporation

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

INCA33890
Placebo
Bevacizumab
FOLFOX

Locations (sample)

Chandler, Arizona, United States|33.30616,-111.84125
Tucson, Arizona, United States|32.22174,-110.92648
Tucson, Arizona, United States|32.22174,-110.92648
Anaheim, California, United States|33.83529,-117.9145
Cerritos, California, United States|33.85835,-118.06479

Key Eligibility Criteria

Stage IV colorectal adenocarcinoma not amenable to curative resection.
No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there w…
Measurable disease per RECIST v1.1.
ECOG performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →